John A. Spertus

Nov 18, 2024 | jamanetwork.com | Mohammad Jawad |Kansas City |John A. Spertus |Uchechukwu Ikeaba

Key PointsQuestion  How has the adoption rate and variation in use of sodium-glucose cotransporter-2 inhibitors (SGLT2is) changed for US patients with heart failure and left ventricular ejection fraction greater than 40% since publication of clinical trial evidence of benefit in 2021?

Oct 30, 2024 | jamanetwork.com | Suzanne Arnold |John A. Spertus |Kensey L. Gosch |Shannon M. Dunlay

Severe tricuspid regurgitation is a common finding in patients with a variety of comorbid conditions, including chronic heart failure, lung disease, pulmonary hypertension, atrial fibrillation, and right ventricular dysfunction and is associated with impaired health status and worse survival.1 Isolated tricuspid valve surgery is associated with relatively high morbidity and/or mortality, often in the setting of concomitant severe right ventricular dysfunction, pulmonary hypertension, and...

Oct 30, 2024 | jamanetwork.com | Suzanne Arnold |Kansas City |John A. Spertus |Shannon M. Dunlay

Key PointsQuestion  Is the Kansas City Cardiomyopathy Questionnaire (KCCQ) a valid disease-specific health status measure in patients with severe tricuspid regurgitation (TR)? Findings  In this cohort study, data on 2693 patients from 11 clinical trials of various transcatheter tricuspid valve interventions (TTVI) from 2 device manufacturers were pooled and then analyzed by an academic analytic center.

Apr 1, 2024 | jacc.org | Reza Mohebi |Philip Jones |John A. Spertus |Ildiko Lingvay

References1. "The importance of worsening heart failure: hiding in plain sight". J Am Coll Cardiol . 2022;80:123-125. https://doi.org/10.1016/j.jacc.2022.04.044. 2. "Treatment for heart failure: endpoints for drug development guidance for industry". Accessed February 5. 2024. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/treatment-heart-failure-endpoints-drug-development-guidance-industry. 3.

Mar 1, 2024 | jacc.org | Andrew Wang |John A. Spertus |Daniel Wojdyla |Theodore P. Abraham

References1. "2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines". J Am Coll Cardiol . 2020;76:e159-e240. 2. "Clinical spectrum and management of heart failure in hypertrophic cardiomyopathy". J Am Coll Cardiol HF . 2018;6:353-363. 3.